Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of actionCombines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multipl...
Pessimistic
-25.0